Related Experiment Video
Updated: Feb 28, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
11.2K
Experience with long-term rituximab use in a multiple sclerosis clinic
Megan E Barra1, Dhruv Soni1, Khac Huy Vo1
1Department of Pharmacy, Brigham and Women's Hospital, USA.
Summary
Long-term rituximab administration in multiple sclerosis patients demonstrated good tolerability and safety. Recurrent dosing of this B-lymphocyte depleting therapy showed a favorable safety profile in clinical practice.
Area of Science:
- Neuroimmunology
- Pharmacology
Background:
- Rituximab, a CD20-targeted monoclonal antibody, is a potential treatment for multiple sclerosis (MS).
- The safety of repeated rituximab dosing in MS patients requires further investigation.
Purpose of the Study:
- To evaluate the long-term safety and efficacy of rituximab in a clinical setting for multiple sclerosis.
- To assess the impact of different dosing regimens on safety outcomes.
Main Methods:
- Retrospective observational study of 107 multiple sclerosis patients treated with rituximab from 2004-2015.
- Analysis of CD19/CD20 counts to monitor B-cell depletion and reconstitution.
- Collection of data on relapses, MRI activity, and adverse events.
Main Results:
- Average treatment duration was 33.2 months, with 77 patients receiving recurrent dosing.
- B-cell (CD19/20) reconstitution occurred around 6 months post-treatment, irrespective of dosing strategy.
- Most side effects were mild; three patients were hospitalized for urinary tract infections. Three patients experienced disease activity despite B-cell depletion.
Conclusions:
- Rituximab is well-tolerated and safe for recurrent administration in multiple sclerosis patients.
- Long-term use in a clinical setting supports rituximab as a viable therapeutic option for MS.
